research News

Stockholm, Sweden – Blood fat-lowering statins could slow the progression of Alzheimer’s disease, at least for some patients. This is the result of a new study led by Karolinska Institutet published in Alzheimer Research and Therapy. But the researchers are cautious in their interpretations and see the results as a...
MEMPHIS, Tenn. – Fibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The disease is caused by a single genetic mutation that creates a fusion protein. Scientists at St. Jude Children’s Research Hospital and The University of Tennessee Health Science Center...
PARIS, France – Professor Francesco Muntoni, principal investigator of the international multicenter gene therapy trial for Duchenne Muscular Dystrophy with GNT0004 product, sponsored by Genethon, presented the innovative trial design and its initial results at the Myology 2024 international scientific congress, currently taking place in Paris. The trial combines phases...
Bethesda, MD — The American Gastroenterological Association (AGA) released a new evidence-based guideline recommending the use of blood and stool-based biomarkers to help manage Crohn’s disease, a type of inflammatory bowel disease (IBD). IBD is estimated to affect 2.74 million people in the U.S. The guideline was published today in...
SYDNEY, Australia — Immutep Limited (formerly known as Prima Biomed), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the first patient has been enrolled and safely dosed in the INSIGHT-005 Phase I trial. The investigator-initiated study jointly funded with Merck KGaA, Darmstadt,...
SAN FRANCISCO – Perspectum announced recruitment of the first patient in a multi-center collaborative study to characterize Primary Sclerosing Cholangitis in children, “Prospective Observational Study of Primary Sclerosing Cholangitis (PSC) in Children.” This 10-year collaborative study includes 12 geographically-diverse children’s hospitals in the United States and one Canadian children’s hospital....
Lund – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first subject has been dosed in phase I clinical study of the newly developed eye-drop formulation of the company’s candidate drug laquinimod. Laquinimod is being developed as a new treatment for non-infectious non-anterior uveitis and has the potential to...
The Gamida Cell-Teva Joint Venture announced today that five prestigious cord blood transplantations centers in Spain, three in Barcelona and two in Valencia, have joined the ExCell study. Participating clinical sites include, in alphabetical order: * Hospital Clínic of Barcelona, Barcelona: Principal Investigator, Dr. Enric Carreras, MD * Hospital Clínico...